UHKT-CAR19 / Institute of Hematology and Blood Transfusion - LARVOL DELTA

UHKT-CAR19-01: CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

POINT-OF-CARE NON-VIRAL PRODUCTION OF CD19 CHIMERIC ANTIGEN RECEPTOR-T CELLS WITH ENHANCED TSCM IMMUNOPHENOTYPE FOR THERAPY OF REFRACTORY B-CELL MALIGNANCIES- PRELIMINARY RESULTS OF PHASE I CLINICAL TRIAL (EHA 2024) - P1 | "This phase I trial uses a dose-escalating scheme, where all patients receive 25 mg/m2/d offludarabine for 5 days and 500 mg/m 2/d of cyclophosphamide for 2 days followed by a single infusion ofUHKT CAR19...The UHKT CAR19 displayed a higher percentageof stem-cell memory CAR-T cells compared to with tisa-cel, in both CD4+ and CD8+ CAR+ T cells... Infusion of UHKT CAR19 was safe and we observed clinical anti-tumor effects in seven out of eleven patients sofar included in the trial. The manufacturing method enables efficient point-of-care production of CAR-T cellswith stem-cell memory phenotype. We are enrolling patients in the high-dose group for the clinical trial."

CAR T-Cell Therapy • Clinical • P1 data • Gene Therapies • CD27 • CD8 • PD-1

UHKT-CAR19-01: CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic | Trial completion date: Jun 2028 ➔ Jun 2025 | Trial primary completion date: Jun 2027 ➔ Dec 2024

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19